

REMARKS:

Summary of Claim Amendments and Pending Claims

Upon entry of the present amendment, claims 75-146 are amended; claims 1-74 are canceled without prejudice or disclaimer. No new matter is added.

The originally filed specification and claims support the present amendments. By entry of the present amendment, claims 75-146 are pending and at issue, and claims 75 and 76 are independent claims.

Applicants reserve the right to file continuation and/or divisional applications directed to subject matter canceled in claims 1-74.

Conclusion

In view of the above, Applicant(s) submit(s) that the application is now in condition for allowance and issue and respectfully request(s) early action to that end. Applicant(s) believe(s) that no additional fees are due. However, should any fees be due, the Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. The undersigned invites the Examiner to contact him/her by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: August 4, 2008

/Richard W. Bork, Reg. No. 36,459/
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800